Ultragenyx Pharmaceutical (RARE)
(Delayed Data from NSDQ)
$44.86 USD
-0.20 (-0.44%)
Updated Jul 26, 2024 04:00 PM ET
After-Market: $44.83 -0.03 (-0.07%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth F Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$44.86 USD
-0.20 (-0.44%)
Updated Jul 26, 2024 04:00 PM ET
After-Market: $44.83 -0.03 (-0.07%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth F Momentum F VGM
Zacks News
What's in Store for Zoetis (ZTS) Stock This Earnings Season?
by Zacks Equity Research
Zoetis Inc. (ZTS) is scheduled to report first-quarter 2017 results on May 4.
What to Expect from Endocyte (ECYT) Stock for Q1 Earnings?
by Zacks Equity Research
Endocyte, Inc (ECYT) is expected to report first-quarter 2017 results on May 3.
What's in Store for Juno Therapeutics (JUNO) in Q1 Earnings?
by Zacks Equity Research
Juno Therapeutics Inc. (JUNO) is scheduled to report first-quarter 2017 results on May 4, after the market closes.
What to Expect from Keryx (KERX) Stock This Earnings Season?
by Zacks Equity Research
Keryx Biopharmaceuticals, Inc. (KERX) is expected to report first-quarter 2017 results on May 4.
BioMarin (BMRN) Q1 Earnings: Will it Beat Estimates Again?
by Zacks Equity Research
We expect BioMarin Pharmaceutical Inc. (BMRN) to beat expectations when it reports first-quarter 2017 results on May 4, after the market closes.
What's in Store for Nivalis (NVLS) this Earnings Season?
by Zacks Equity Research
Nivalis Therapeutics, Inc. (NVLS) is expected to report first-quarter 2017 results early next month. Last quarter, the company had a positive surprise of 9.09%.
What's in Store for Vertex (VRTX) this Earnings Season?
by Zacks Equity Research
Vertex Pharmaceuticals, Inc. (VRTX) is scheduled to report first-quarter 2017 results on Apr 27, after the market closes.
What's in Store for AbbVie (ABBV) this Earnings Season?
by Zacks Equity Research
AbbVie Inc. (ABBV) is slated to release first-quarter 2017 earnings, before the opening bell on Apr 27.
Company News for April 20, 2017
by Zacks Equity Research
Companies in the News are: LRCX,FB,RARE,ABT
Ultragenyx's Hypophosphatemia Drug Succeeds in Phase III
by Zacks Equity Research
Ultragenyx Pharmaceutical Inc. (RARE) and its Japanese partner Kyowa Hakko Kirin Co., Ltd announced positive data from a phase III study evaluating its pipeline candidate burosumab (KRN23) in adults with X-linked hypophosphatemia (XLH).
Ultragenyx's (RARE) XLH Drug Positive in Phase II Study
by Zacks Equity Research
Ultragenyx Pharmaceutical Inc. (RARE) and its Japanese partner Kyowa Kirin International plc recently announced positive 64-week data from a pediatric phase II study, evaluating its investigational candidate burosumab (KRN23).
Ultragenyx's Seizure Candidate UX007 Fails in Phase II Study
by Zacks Equity Research
Ultragenyx Pharmaceutical Inc. (RARE) recently announced that its pipeline candidate UX007 (triheptanoin) failed to meet the primary endpoint in a phase II study evaluating it for the treatment of patients with Glut1 DS with seizures.
Ultragenyx's (RARE) KRN23 Accepted for Review in the EU
by Zacks Equity Research
Ultragenyx (RARE) announced that EMA has accepted to review its MAA for KRN23 for the treatment of X-linked hypophosphatemia.
Ultragenyx (RARE) Reports Positive Phase II Study on UX007
by Zacks Equity Research
Ultragenyx (RARE) announced positive data from a phase II study on UX007 for the treatment of patients with long-chain fatty acid oxidation disorder (LC-FAOD).